By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Zealand Pharma A/S  

Smedeland 26 B

Glostrup    DK-2600  Denmark
Phone: 45-43-28-12-00 Fax: 45-43-28-12-12


Company News
Zealand Pharma  (ZEAL.CO) Release: The U.S. FDA Approves Soliqua 100/33 For The Treatment Of Adults With Type 2 Diabetes 11/22/2016 7:00:58 AM
Zealand Pharma  (ZEAL.CO) Release: CHMP Issues Positive Opinion Recommending Suliqua (Iglarlixi) For Approval In The EU 11/11/2016 8:51:51 AM
Zealand Pharma  (ZEAL.CO) Raises DKK 143 Million Via Private Placement 9/30/2016 6:18:16 AM
Zealand Pharma  (ZEAL.CO) Release: Royalty Report For Q2 2016 And Update On Lixisenatide (Lyxumia/Adlyxintm) And Iglarlixi 7/29/2016 7:58:13 AM
Zealand Pharma  (ZEAL.CO) Convenes Its Annual General Meeting For 2016 3/18/2016 8:10:26 AM
Zealand Pharma  (ZEAL.CO) Announces That Sanofi (SNY)s NDA For The Fixed-Ratio Combination (Lixilan) Of Lixisenatide And Insulin Glargine For Type 2 Diabetes Has Been Accepted For Review By The FDA 2/22/2016 11:47:15 AM
Zealand Pharma  (ZEAL.CO) Doses The First Patients With ZP1848 For Short Bowel Syndrome, Advancing The Second Of Its Proprietary Specialty Medicines Into Phase II Development In 2016 2/15/2016 7:33:46 AM
Zealand Pharma  (ZEAL.CO) Clarifies Its Role In U.S. Patent Litigation Relating To Lixisenatide And Confirms Its Confidence In A Strong Patent Status For The Product 2/5/2016 7:28:02 AM
Sanofi (SNY) Pays $20 Million Milestone and Redeems Priority Review Voucher for Zealand Pharma  (ZEAL.CO)’s LixiLan 12/23/2015 6:41:28 AM
Zealand Pharma  (ZEAL.CO) Is Ready To Take Next Steps In A Diligent Growth Strategy For Accelerated Value Creation: From Peptide To Patient 11/4/2015 8:19:15 AM